Condition
Angioimmunoblastic T-cell Lymphoma clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Angioimmunoblastic T-cell Lymphoma clinical trials that are recruiting, at sites in 3 countries (most in United States (5), Australia (1), Canada (1)). By phase: Phase 1 (2), Phase 3 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 3Countries
Newest Angioimmunoblastic T-cell Lymphoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Azacitidine and abatacept for relapsed or refractory T-cell lymphoma | Phase 1 | Bethesda, Maryland | Recruiting | Feb 5, 2026 |
| Comparing soquelitinib to standard treatments for certain types of relapsed T-cell lymphoma | Phase 3 | Duarte, California and 36 other locations | Recruiting | Aug 19, 2024 |
| Registry for individuals with T-cell lymphoma | — | Duarte, California and 25 other locations | Recruiting | Aug 7, 2023 |
| Testing new treatments for peripheral T-cell lymphoma | Phase 2 | Little Rock, Arkansas and 95 other locations | Recruiting | Mar 17, 2021 |
| Testing a new treatment for relapsed T-cell non-Hodgkin lymphoma | Phase 1 | Scottsdale, Arizona and 9 other locations | Recruiting | Jan 21, 2020 |
All recruiting trials (5)
-
Azacitidine and abatacept for relapsed or refractory T-cell lymphoma
This study tests a combination of azacitidine and abatacept to see if it can shrink tumors in adults whose T-cell lymphoma has come back or not responded to treatment.
-
Comparing soquelitinib to standard treatments for certain types of relapsed T-cell lymphoma
This study is testing if a new pill called soquelitinib can work better than regular treatments for people with certain types of relapsed T-cell lymphoma.
-
Registry for individuals with T-cell lymphoma
This study is gathering information from people with T-cell lymphoma to help researchers learn more about the disease and improve treatments.
-
Testing new treatments for peripheral T-cell lymphoma
This study is testing whether adding new drugs, duvelisib or CC-486, to standard chemotherapy can help people with peripheral T-cell lymphoma achieve better treatment results.
-
Testing a new treatment for relapsed T-cell non-Hodgkin lymphoma
This study is testing a new treatment called ST-001 to see if it can help people with relapsed T-cell non-Hodgkin lymphoma feel better and have fewer side effects.
Related topics
Quick answers
How many Angioimmunoblastic T-cell Lymphoma clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (5 trials), Australia (1 trial), Canada (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 3: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.